Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 259

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Stimulation of Endothelial Progenitor Cells: A New Putative Therapeutic Effect of Angiotensin II Receptor Antagonists

Open access
Bahlmann, Ferdinand H., de Groot, Kirsten, Mueller, Ottfried, Hertel, Barbara, Haller, Hermann, Fliser, Danilo·2005·Hypertension

Abstract

The number of circulating endothelial progenitor cells (EPCs) correlates with endothelial dysfunction and cardiovascular risk in humans. We explored whether angiotensin II receptor antagonist therapy affects the number of regenerative EPCs in patients with type 2 diabetes. In a prospective double-blind parallel group study, we randomly treated 18 type 2 diabetics with olmesartan (40 mg) or placebo for 12 weeks. We analyzed circulating CD34 + hematopoietic progenitor cells (flow cytometry) and EPCs (in vitro assay) before and after therapy. We verified the results in a second open trial treating 20 type 2 diabetics with 300 mg of irbesartan for 12 weeks. The number of EPCs was significantly lower in diabetic patients as compared with 38 age-matched healthy subjects (210±10 versus 258±18 per high-power field; P <0.05), whereas there was no significant difference with respect to hematopoietic progenitor cells. Treatment with olmesartan (n=9) significantly increased EPCs from 231±24 to 465±71 per high-power field ( P <0.05), but not hematopoietic progenitor cells. In contrast, placebo treatment (n=9) did not affect EPCs and hematopoietic progenitor cells. With irbesartan therapy, EPC number increased significantly from 196±15 to 300±23 per high-power field ( P <0.05) already after 4 weeks of treatment. At the end of 12-week therapy, patients had 310±23 EPCs per high-power field ( P <0.05 versus baseline). Angiotensin II receptor antagonists increase the number of regenerative EPCs in patients with type 2 diabetes mellitus. This action may be of therapeutic relevance contributing to their beneficial cardiovascular effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.hyp.0000159191.98140.89

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 259

Metadata

Authors
Bahlmann, F. H., de Groot, K., Mueller, O., Hertel, B., Haller, H., & Fliser, D.
Venue
Hypertension
Published
2005-04
Volume
45
Issue
4
Pages
526-529
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W1999582512
Cited by
259
References
24
FWCI
8.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stimulation of Endothelial Progenitor Cells: A New Putative Therapeutic Effect of Angiotensin II Receptor Antagonists. https://app.cochat.ai/papers/10.1161/01.hyp.0000159191.98140.89
The paper
Bahlmann, F. H., de Groot, K., Mueller, O., Hertel, B., Haller, H., & Fliser, D. (2005). Stimulation of Endothelial Progenitor Cells: A New Putative Therapeutic Effect of Angiotensin II Receptor Antagonists. Hypertension. https://doi.org/10.1161/01.hyp.0000159191.98140.89

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.